Search alternatives:
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
-
1301
-
1302
Loss of ALS2 results in decreased levels of the lysosome-dependent degradation of LC3 in fibroblasts.
Published 2010“…Fibroblasts derived from either wild-type (<i>Als2</i><sup>+/+</sup>) or <i>Als2</i><sup>−/−</sup> mice were incubated in a starvation medium with or without 0.5 µM chloroquine (CQ) for 6 hr. …”
-
1303
Decreased HIF levels associated with hyperoxic cell state.
Published 2008“…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
-
1304
Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>.
Published 2015“…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
-
1305
-
1306
-
1307
-
1308
-
1309
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
1310
-
1311
-
1312
-
1313
-
1314
-
1315
-
1316
-
1317
-
1318
-
1319
-
1320